OTLK (Outlook Therapeutics) Tariff Resilience Score: 4/10 (As of Jul. 08, 2026)


OTLK Outlook Therapeutics Inc OTLK
16 GF Score
Price $1.60
! 5 Warning Signs
View Full Analysis

What is Outlook Therapeutics Tariff Resilience Score?

Outlook Therapeutics OTLK +9.97% 16 Tariff Resilience Score is 4 as of Jul. 08, 2026. GuruFocus rates OTLK with a GF Score™ of 16/100. The stock has 5 warning signs investors should review. Among 1,367 Biotechnology companies, Outlook Therapeutics ranks better than 52.45% on this metric.

Outlook Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Outlook Therapeutics has Outlook Therapeutics is vulnerable due to its reliance on international suppliers for raw materials. The company has limited mitigation strategies and has been affected by past tariff changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Outlook Therapeutics might have Average Resilient.

Outlook Therapeutics  (NAS:OTLK) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Outlook Therapeutics Tariff Resilience Score Related Terms

OTLK vs FULC, OBIO, ACIU: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Tariff Resilience Score falls into.


OTLK
16GF Score
Outlook Therapeutics Inc OTLK
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Outlook Therapeutics (OTLK) has a Tariff Resilience Score of 4 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Outlook Therapeutics ranks #650 out of 1367 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Outlook Therapeutics' Tariff Resilience Score too high?
Outlook Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Outlook Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Outlook Therapeutics ranks #650 out of 1367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Outlook Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Tariff Resilience Score compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #650 out of 1367 companies for Tariff Resilience Score. This puts Outlook Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Outlook Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Outlook Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Outlook Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Tariff Resilience Score is 4 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
16GF Score

Get the complete analysis for OTLK

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price